Immune Cell Signaling Laboratory
Our
Projects
Since the start of the laboratory (February 2019), we secured funding from several Govt. funding agencies and BITS-Pilani to identify a novel class of gut-microbiota-derived metabolites to treat intestinal inflammation and associated malignancies.
DST-SERB ECRA
(December 2018, 42 Lakhs)-PI
Identification of novel bile acid derivatives regulating intestinal cancer. Towards this, we have identified a bile acid that regulates expression of soluble WNT isoforms in macrophages treated with PRRs.
CSIR
(August 2019, 19.5 Lakhs)-PI
Deciphering the role of bile acids regulating immune cell functions. Towards this, we are aiming to identify the negative regulators of inflammation in activated macrophages and study the impact of activated macrophages on EMT
RIG, BITS and Add. CRG, BITS
(August 2017 & May 2018, 11 Lakhs)-PI
Quantification of small molecule metabolites in macrophages that drive differentiation of macrophages towards pro-/anti-inflammatory phenotype have been identified using HPLC
ICMR-DHR
(October 2021, 19 Lakhs to BITS)-Co-Investigator
PI-Dr. Aparna Sreekantam, M.D. Head-research and Director-Lab, LEPRA-BPHRC.
Centre for Human Disease Research (CHDR-BITS-Pilani)
(August 2018- Till Date)
in collaboration with Prof. Yogeeswari, Prof. Sriram, and Prof. Sajeli Begum-Identification of novel small molecule inhibitors to treat cancer/tuberculosis infections
